Rhumbline Advisers Grows Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Rhumbline Advisers boosted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.6% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 90,587 shares of the company’s stock after acquiring an additional 1,394 shares during the period. Rhumbline Advisers’ holdings in Amphastar Pharmaceuticals were worth $3,623,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Amphastar Pharmaceuticals by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 2,815,596 shares of the company’s stock valued at $174,145,000 after acquiring an additional 48,203 shares during the period. Epoch Investment Partners Inc. raised its position in Amphastar Pharmaceuticals by 34.8% in the first quarter. Epoch Investment Partners Inc. now owns 798,462 shares of the company’s stock valued at $35,060,000 after purchasing an additional 205,932 shares during the period. TD Asset Management Inc lifted its stake in Amphastar Pharmaceuticals by 449.0% during the fourth quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock worth $49,082,000 after purchasing an additional 649,001 shares in the last quarter. Boone Capital Management LLC acquired a new position in Amphastar Pharmaceuticals during the fourth quarter worth $24,740,000. Finally, Bessemer Group Inc. boosted its position in shares of Amphastar Pharmaceuticals by 21.5% during the first quarter. Bessemer Group Inc. now owns 395,941 shares of the company’s stock worth $17,387,000 after buying an additional 69,968 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Insider Activity at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 4,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now directly owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Rong Zhou sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the transaction, the executive vice president now owns 118,388 shares in the company, valued at $5,724,059.80. The disclosure for this sale can be found here. Insiders have sold 37,979 shares of company stock valued at $1,671,307 in the last ninety days. Insiders own 27.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on AMPH shares. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler cut their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, September 12th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $63.00.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $48.38 on Tuesday. The business’s 50-day moving average is $43.66 and its two-hundred day moving average is $42.53. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The firm has a market capitalization of $2.36 billion, a P/E ratio of 16.74, a P/E/G ratio of 0.85 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The company had revenue of $182.39 million during the quarter, compared to the consensus estimate of $171.29 million. Analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.